奥卡西平治疗下的低钠血症昏迷

Hyponatremic coma under oxcarbazepine therapy.

作者信息

Steinhoff B J, Stoll K D, Stodieck S R, Paulus W

机构信息

Neurologische Klinik, Ludwig-Maximilians-Universität München, Germany.

出版信息

Epilepsy Res. 1992 Mar;11(1):67-70. doi: 10.1016/0920-1211(92)90023-m.

DOI:10.1016/0920-1211(92)90023-m

PMID:1563340

Abstract

Oxcarbazepine (OXC) is considered to be a promising new antiepileptic drug with similar efficacy and better tolerability compared to carbamazepine (CBZ). However, hyponatremia is supposed to occur even more often than with CBZ. We report on a patient who developed hyponatremic coma under OXC with a serum sodium level of 115 mmol/l, the second published case of OXC-induced hyponatremia with serious clinical adverse effects.

摘要

奥卡西平（OXC）被认为是一种很有前景的新型抗癫痫药物，与卡马西平（CBZ）相比，疗效相似且耐受性更好。然而，据推测，低钠血症的发生率甚至比使用CBZ时更高。我们报告了一名在服用OXC期间发生低钠血症昏迷的患者，其血清钠水平为115 mmol/L，这是第二例已发表的由OXC引起的低钠血症并伴有严重临床不良反应的病例。